Gene therapy: Industrial strength.
Eric
E
Bender
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000235:genetics / Q000628:therapy; D002986:Clinical Trials as Topic; D000229:Dependovirus / Q000235:genetics; D004285:Dogs; D017277:Drug Approval; D015316:Genetic Therapy / Q000009:adverse effects / Q000191:economics / Q000639:trends*; D005822:Genetic Vectors / Q000009:adverse effects / Q000235:genetics; D006402:Hematologic Diseases / Q000235:genetics / Q000628:therapy; D018259:Herpesvirus 1, Human / Q000235:genetics; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D009369:Neoplasms / Q000235:genetics / Q000628:therapy; D061214:Patient Safety; D057285:Precision Medicine / Q000009:adverse effects / Q000191:economics / Q000379:methods* / Q000639:trends*; D035583:Rare Diseases / Q000235:genetics / Q000628:therapy; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal